Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of N-acetylcysteine (NAC) in the treatment on bulimia nervosa.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Men or women, between the ages of 18 and 65. The patient population is expected to be predominantly made up of women based on previous research.
Patients will meet DSM-IV-TR criteria for BN for at least the last 6 months. These criteria are as follows:
A. Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following:
C. Binge-purge episodes occur at least two times a week in the last 3 months D. Self- evaluation in unduly influenced by body shape and weight E. The disturbance does not occur exclusively during episodes of anorexia nervosa.
Capacity to consent to the study and comply with study procedures.
Exclusion criteria
Criteria for exclusion from this study will be any of the following:
Subjects who are taking psychotropic medications will be allowed into the study as long as the dose of medication had been stable for 3 months before study inclusion and there are no plans to modify the dose during the study duration. Similarly, subjects evolved in psychotherapy for BN will be allowed to participate if attendance had been ongoing for at least 3 months before study entry. Subjects who changed doses of medication or started new therapy will be discontinued from the study.
Primary purpose
Allocation
Interventional model
Masking
11 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal